Cite
HARVARD Citation
Guarneri, V. et al. (2015). Prospective Biomarker Analysis of the Randomized CHER‐LOB Study Evaluating the Dual Anti‐HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2‐Positive Breast Cancer. Oncologist. pp. 1001-1010. [Online].